Cargando…
Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study
BACKGROUND: Targeting signaling pathways is an attractive approach in many malignancies. The PI3K/Akt/mTOR pathway is activated in a number of human neoplasms, accompanied by lower overall and/or disease free survival. mTOR kinase inhibitors have been introduced in the therapy of renal cell carcinom...
Autores principales: | Márk, Ágnes, Hajdu, Melinda, Váradi, Zsófia, Sticz, Tamás Béla, Nagy, Noémi, Csomor, Judit, Berczi, Lajos, Varga, Viktória, Csóka, Monika, Kopper, László, Sebestyén, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665449/ https://www.ncbi.nlm.nih.gov/pubmed/23693095 http://dx.doi.org/10.1186/1471-2407-13-250 |
Ejemplares similares
-
Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)
por: Nemes, Karolina, et al.
Publicado: (2013) -
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease
por: Váradi, Zsófia, et al.
Publicado: (2017) -
Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
por: Felkai, Luca, et al.
Publicado: (2020) -
In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma
por: Mohás, Anna, et al.
Publicado: (2022) -
Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature
por: Balogh, Petra, et al.
Publicado: (2016)